Oncology News

ESMO oncology news ensures that you're always kept up to date with the latest developments that affect you and your daily practice. Make sure you check these pages frequently, or sign up to our newsletter.

Filter

Date Title Topic
17 May 2017 NaviCam for Diagnosing Gastrointestinal Tract Conditions Diagnosis, Imaging and Staging
16 May 2017 Severe Skin Reactions from Pembrolizumab Palliative and supportive care - Cancer Immunology and Immunotherapy
15 May 2017 FDA Approves Ribociclib-Letrozole Co-Pack for Initial Treatment of HR-positive/HER2-negative Advanced or Metastatic Breast Cancer Breast cancer - Anticancer agents & Biologic therapy
12 May 2017 FDA Approves Pembrolizumab as First-Line Combination Therapy with Pemetrexed and Carboplatin for Metastatic Non-squamous NSCLC Irrespective of PD-L1 Expression Lung and other thoracic tumours - Cancer Immunology and Immunotherapy
11 May 2017 NICE Issues Technology Appraisal Guidance for Pegylated Liposomal Irinotecan Gastrointestinal cancers - Anticancer agents & Biologic therapy
10 May 2017 FDA Grants Accelerated Approval to Avelumab for Urothelial Carcinoma Genitourinary cancers - Cancer Immunology and Immunotherapy
04 May 2017 IMPAKT 2017: High Baseline TIL Levels Signal Superior Responses in HER2-Positive Breast Cancer Breast cancer
04 May 2017 IMPAKT 2017: Luminal Androgen Receptor (LAR) Subtype of Triple Negative Breast Cancer (TNBC) Demonstrates In Vitro and In Vivo Sensitivity to CDK4/6 Inhibition Breast cancer - Translational research - Basic science
04 May 2017 IMPAKT 2017: Few Variations in Somatic Mutations Observed Between Pregnant and Non-Pregnant Patients with Breast Cancer Breast cancer - Cancer in Special Situations - Translational research
03 May 2017 FDA Grants Accelerated Approval to Durvalumab for Locally Advanced or Metastatic Urothelial Carcinoma Genitourinary cancers - Cancer Immunology and Immunotherapy
03 May 2017 FDA Approves Midostaurin and a Companion Diagnostic Personalised medicine - Haematologic malignancies - Anticancer agents & Biologic therapy
02 May 2017 FDA Grants Accelerated Approval to Brigatinib and Breakthrough Therapy Designation to Lorlatinib Personalised medicine - Lung and other thoracic tumours - Anticancer agents & Biologic therapy
28 Apr 2017 FDA Expands Indications for Regorafenib Gastrointestinal cancers - Anticancer agents & Biologic therapy
27 Apr 2017 EMA Recommends Approval of Two Biosimilar Medicines – Biosimilar Rituximab Haematologic malignancies - Anticancer agents & Biologic therapy
26 Apr 2017 EMA Recommends Granting a Marketing Authorisation for Inotuzumab Ozogamicin Haematologic malignancies - Anticancer agents & Biologic therapy